Primary ovarian high-grade endometrial stromal sarcoma: a case report

Abstract Background Primary ovarian high-grade endometrial stromal sarcoma is a very rare disease. Even though it has poor prognosis, the gold standard treatment has not been established owing to its rarity. This report aimed to present therapeutic options for primary ovarian high-grade endometrial stromal sarcoma. Case presentation A 49-year-old Asian woman presented with disseminated intravascular coagulation due to ruptured primary high-grade ovarian endometrial stromal sarcoma with multiple intraperitoneal metastases. After the initial surgery, the patient underwent adjuvant chemotherapy with three courses of Adriamycin (75 mg/m2). We performed the secondary debulking operation including total hysterectomy, metastasectomy, omentectomy, peritonectomy, appendectomy, and hyperthermic intraperitoneal chemotherapy (paclitaxel 175 mg/m2). Currently she has been alive for 28 months under a new chemotherapy regimen. Conclusion We suggest cytoreductive surgery with hyperthermic intraperitoneal chemotherapy could be a therapeutic option for primary high-grade ovarian endometrial stromal sarcoma with peritoneal dissemination.

Download Full-text

Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Recurrent Endometrial Carcinoma Confined to the Peritoneal Cavity

International Journal of Gynecological Cancer ◽

10.1111/igc.0b013e3181a83f7e ◽

2010 ◽

Vol 20 (5) ◽

pp. 809-814 ◽

Cited By ~ 17

Author(s):

Naoual Bakrin ◽

Eddy Cotte ◽

Anne Sayag-Beaujard ◽

Daniel Raudrant ◽

Sylvie Isaac ◽

...

Keyword(s):

Endometrial Carcinoma ◽

Peritoneal Cavity ◽

Intraperitoneal Chemotherapy ◽

Cytoreductive Surgery ◽

Hyperthermic Intraperitoneal Chemotherapy ◽

Therapeutic Option ◽

Performance Status ◽

Early Recurrence ◽

Gynecology And Obstetrics ◽

Initial Surgery

Our objective was to determine if cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a feasible therapeutic option for treatment of peritoneal recurrence of endometrial carcinoma. Between August 2002 and May 2007, 5 patients with recurrent endometrial carcinoma confined to the peritoneal cavity who underwent CRS with HIPEC. Cisplatin (1 mg/kg) and mitomycin C (0.7 mg/kg) were perfused at an inflow temperature of 46 to 48°C for 90 minutes under systemic hypothermia (32°C). Of the 5 patients treated, histopathological type and International Federation of Gynecology and Obstetrics stage were as follows: IB endometrioid (n = 1), IIIA endometrioid (n = 1), IIIC endometrioid (n = 2), and IC endometrioid + pseudosarcomatoid component (n = 1). The mean interval from initial surgery to CRS with HIPEC was 47.5 months (10-120 months). In all patients, CRS was complete. One patient with pseudosarcomatoid component developed recurrent disease 10 months after surgery and died 2 months later. One patient experienced early recurrence with a malignant pleural effusion and died. Three patients are alive and disease free at 7, 23, and 39 months from surgery with good performance status. Regarding the toxicity of the procedure, highly selected patients with recurrent endometrial carcinoma confined to the peritoneal cavity may benefit from improved survival after CRS with HIPEC.

Download Full-text

High-grade Endometrial Stromal Sarcoma With BCOR Gene Alterations is Recommended as an Independent Subtype of Endometrial Carcinoma: A Case Report

10.21203/rs.3.rs-47553/v1 ◽

2020 ◽

Author(s):

Feng LING ◽

Sibei Ruan ◽

Na Li ◽

XiaoMing Xiong ◽

DongMei Zhao ◽

...

Keyword(s):

Endometrial Stromal Sarcoma ◽

World Health ◽

Uterine Leiomyosarcoma ◽

Tumour Mass ◽

High Grade ◽

Case Presentation ◽

Stromal Sarcoma ◽

Health Organization ◽

Pathological Report ◽

Gene Alterations

Abstract Background:The uterine leiomyosarcoma combined high-grade endometrial stromal sarcoma (HGESS) with BCOR gene alterations is exceedingly rare. The subtype of YWHAE-FAM22 HGESS is shown in the current World Health Organization classification, but not HGESS with BCOR alterations. Case presentation: We reported such a case in which HGESS with BCOR gene alterations and leiomyosarcoma coexist in a patient. And, most impressively, HGESS with BCOR gene alterations caused ovarian and pelvic metastases, although its volume was less than 1% of leiomyosarcoma.Conclusions: Given the more aggressive of HGESS with BCOR gene alterations, we suggest that it is classified as an independent subtype of HGESS, and when it coexists with other types of tumors, the HGESS with BCOR gene alterations needs to be noted in the pathological report even if it accounts for less than 1% of the tumour mass.

Download Full-text

Is high-grade endometrial stromal sarcoma the key to disease prognosis in cases of coexisting leiomyosarcoma? A case report

10.21203/rs.3.rs-37376/v1 ◽

2020 ◽

Author(s):

Feng Ling ◽

Sibei Ruan ◽

XiaoMing Xiong ◽

Na Li ◽

DongMei Zhao ◽

...

Keyword(s):

Case Report ◽

Endometrial Stromal Sarcoma ◽

Uterine Leiomyosarcoma ◽

Tumour Mass ◽

High Grade ◽

Case Presentation ◽

Stromal Sarcoma ◽

Disease Prognosis ◽

Pathological Report ◽

Gene Alterations

Abstract Background:The uterine leiomyosarcoma combined high-grade endometrial stromal sarcoma (ESS) is quite rare.Case presentation: We reported such a case in which high-grade ESS with BCOR gene alterations and leiomyosarcoma coexist in a patient. And, most impressively, high-grade ESS with BCOR gene alterations caused ovarian and pelvic metastases, although its volume was less than 1% of leiomyosarcoma.Conclusions: We suggested that when both high-grade ESS BCOR gene alterations and leiomyosarcoma are present in a patient, the high-grade ESS needs to be noted in the pathological report even if it accounts for less than 1% of the tumour mass.

Download Full-text

HIGH-GRADE ENDOMETRIAL STROMAL SARCOMA :A CASE REPORT

10.36106/gjra/4008927 ◽

2019 ◽

pp. 1-3

Author(s):

S. Berrada ◽

K. Benchakroun ◽

M. El Hassani ◽

J. Kouach ◽

D. Moussaoui

Keyword(s):

Poor Prognosis ◽

Tumor Necrosis ◽

Standard Treatment ◽

Endometrial Stromal Sarcoma ◽

Pathological Examination ◽

High Grade ◽

Postmenopausal Bleeding ◽

Uterine Sarcomas ◽

Stromal Sarcoma ◽

High Mitotic Activity

Uterine sarcomas are tumors of poor prognosis characterized by a great histopathological heterogeneity. High endometrial stromal sarcomas (ESS) occurring at a late age, with high mitotic activity and / or tumor necrosis, are very poorly prognostic tumors. If it is accepted that the standard treatment of uterine sarcomas is surgical, the place of adjuvant treatment remains controversial. We report a case of a high-grade ESS referred to initially on MRI and diagnosed on pathological examination of a hysterectomy performed in a 64-year-old postmenopausal woman with postmenopausal bleeding.

Download Full-text